The first #cancer drug approved based on its effect on a specific mutation in a #tumor. @US_FDA approved the drug larotrectinib (Vitrakvi®; LOXO-101) for cancers caused by a genetic mutation called a TRK fusion. https://t.co/cassn7jJu0 https://t.co/svYDNxc
RT @pashtoonkasi: @CathyEngMD @NatRevClinOncol 📌Yet another target for a subset of patients with colon & rectal cancers; other GI cancers a…
RT @pashtoonkasi: @CathyEngMD @NatRevClinOncol 📌Yet another target for a subset of patients with colon & rectal cancers; other GI cancers a…
RT @pashtoonkasi: @CathyEngMD @NatRevClinOncol 📌Yet another target for a subset of patients with colon & rectal cancers; other GI cancers a…
@CathyEngMD @NatRevClinOncol 📌Yet another target for a subset of patients with colon & rectal cancers; other GI cancers as well. ✅💡Brings the question of universal comprehensively profiling upfront. The benefit is real @nejm. #CRCSM #PancSM @curecc
新規分子標的薬ラロトレクチニブ、TRK融合遺伝子陽性がんに奏効/NEJM Carenet医療ニュース #carenet https://t.co/uhaOD3sMBh … larotrectinib 「トロポミオシン受容体」という言葉がどこで紛れ込んできたのかわからない。 https://t.co/yqHI6Lkfxq … つながらない。https://t.co/cpd9RLNU7V
Benayed #NGDx18 LOXO NTRK ref '18 https://t.co/Qlowi6Yuk5 Describes MSK-IMPACT 70 introns of 20 re-arr genes.
Ladanyi #NGDx18 Shows cancer type-agnostic examples - ERBB2, NTRK fusions. '18 NEJM https://t.co/Qlowi7g5IF
RT @RandFanshier: 75% successful in knocking out cancer in adults that has the specific genetic code. #larotrectinib https://t.co/fgoJlDGTmP
75% successful in knocking out cancer in adults that has the specific genetic code. #larotrectinib https://t.co/fgoJlDGTmP
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.c…
Exciting study highlighting the potential of #PrecisionMedicine done right: the right target and the right drug, regardless of cancer type. Very impressive responses seen in adults and children with a wide range of cancer types. #CancerResearch https://t.c
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @PrashantBavi: @KaitlinSundling @TheUSCAP @smlungpathguy @erikacytogal @Dr_DR_Cells @Sinchita_Roy @ALBoothMD 1. NEJM NTRK fusions articl…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @PrashantBavi: @KaitlinSundling @TheUSCAP @smlungpathguy @erikacytogal @Dr_DR_Cells @Sinchita_Roy @ALBoothMD 1. NEJM NTRK fusions articl…
RT @PrashantBavi: @KaitlinSundling @TheUSCAP @smlungpathguy @erikacytogal @Dr_DR_Cells @Sinchita_Roy @ALBoothMD 1. NEJM NTRK fusions articl…
RT @PrashantBavi: @KaitlinSundling @TheUSCAP @smlungpathguy @erikacytogal @Dr_DR_Cells @Sinchita_Roy @ALBoothMD 1. NEJM NTRK fusions articl…
RT @PrashantBavi: @KaitlinSundling @TheUSCAP @smlungpathguy @erikacytogal @Dr_DR_Cells @Sinchita_Roy @ALBoothMD 1. NEJM NTRK fusions articl…
@KaitlinSundling @TheUSCAP @smlungpathguy @erikacytogal @Dr_DR_Cells @Sinchita_Roy @ALBoothMD 1. NEJM NTRK fusions article https://t.co/om9aLuQ9G1 ..🙏@smlungpathguy 2. Neoadjuvant systemic therapy(NAST), use of newer imaging modalities to assess collagen
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
RT @smlungpathguy: At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with…
At #USCAP2018 I learned about a recent study that showed larotrectinib was active against a variety of tumor types with TRK fusions REGARDLESS of tumor type. I probably can't use this info in practice, but I found it interesting. What did u learn? htt
RT @HartungIngo: Tissue-agnostic cancer drugs are clearly on the rise as now featured in @NatRevDrugDisc: https://t.co/3IlrN2PO46. And with…
RT @HartungIngo: Tissue-agnostic cancer drugs are clearly on the rise as now featured in @NatRevDrugDisc: https://t.co/3IlrN2PO46. And with…
Tissue-agnostic cancer drugs are clearly on the rise as now featured in @NatRevDrugDisc: https://t.co/3IlrN2PO46. And with clinical data such as those recently reported in @NEJM it is not a surprise anymore: https://t.co/0hAU3ZMGf0 https://t.co/HoLApET7Mc
Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type. https://t.co/byIVvobPSb
RT @InovaCPH: The Inova Schar Cancer Institute at @InovaHealth was thrilled to be a trial site for this important cancer drug research: htt…
The Inova Schar Cancer Institute at @InovaHealth was thrilled to be a trial site for this important cancer drug research: https://t.co/7zjT0bcGrD @doctorskippy @tstottle @RunWineOpine
Another rare mutation w new exciting treatment options: Larotrectinib in +TRK fusion cancers including #lungcancer #lcsm https://t.co/i5oZm8TWKv
RT @docjunaid: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/Cfe4cOoQam
RT @docjunaid: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/Cfe4cOoQam
RT @DanLeeMD: Exciting report on an important class of targeted cancer drugs. Check out the abstract: Efficacy of Larotrectinib in TRK Fus…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/Cfe4cOoQam
Exciting report on an important class of targeted cancer drugs. Check out the abstract: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/wxP0oYeeAf
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @GrupoGeis: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/xOycG1l97j
RT @GrupoGeis: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/xOycG1l97j
RT @GrupoGeis: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/xOycG1l97j
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/xOycG1l97j
RT @NCIDirector: Great result in children and adults with NTRK fusion-driven cancers. Finding these patients will require early RNA/DNA ana…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
このsarcomaの、めっちゃ効いてる例と全く効いてない例のゲノムの比較をお願いします。 https://t.co/S8fx9M8G8X
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
激しいウォーターフォールプロットだ… https://t.co/EGALsXb6aG
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https:/…
Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD https://t.co/e2NKbxT58e
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/UtDpftMLLg #umkcclintrial #umkcbiomed
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @NReguart: Here it is!!! We were waiting for it, treating all cancers the same just based on a common genomic alteration, TRK-fusion. Ac…
New post in Dev.of Pharmacy Career Channel: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/gSecYl9z8e https://t.co/tUGCTtLVuc
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/c1XMjjkdv8
Efficacy of #Larotrectinib in #TRK Fusion–Positive #Cancers in #Adults and #Children | #NEJM https://t.co/Lwq2e3r8ds
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @mlazqui: Efficacy of #Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/YuithGm9d8
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @tmprowell: Dr. Theodore Laetsch of @UTSouthwestern attributes efficiency of dev program targeting rare gene fusion in #cancer to intens…
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
RT @IASLC: New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor use…
New paper by @alexdrilon and colleagues evaluates the safety and efficacy of larotrectinib, a highly-selective TRK inhibitor used to treat adults and children with TRK fusion–positive cancers. #LCSM @sloan_kettering https://t.co/9pSvoMpUeN
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @OncoblogBulbul: Pembro for MSI-H tumors (https://t.co/XfvjkJ7fIY…). Larotrectinib for TRK fusions (https://t.co/GJbRzUVy9T). This is…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @OncoblogBulbul: Pembro for MSI-H tumors (https://t.co/XfvjkJ7fIY…). Larotrectinib for TRK fusions (https://t.co/GJbRzUVy9T). This is…
RT @carlos_macki: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/GfKjRWMlEi
RT @sjmjones: A wonderful example of precision oncology making real progress with a 75-80% response rate in targetted tumours https://t.co/…
RT @sjmjones: A wonderful example of precision oncology making real progress with a 75-80% response rate in targetted tumours https://t.co/…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…
RT @NEJM: Original Article: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/rhm49T26SD Editor…